The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Open accessAbstract
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cardiovascular disease (CVD) remains a significant threat to people with obesity and type 2 diabetes (T2D), with a two to three times higher incidence compared to people without diabetes or obesity [1, 2].”
From Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Research works printed but not linked: 2
- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. · DOI · Paper page
- Disease C, Management R. Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103-s123.
Cited by
Sorted by citations
Items 301–400 of 472
Xie, H., & Jiang, M.-J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s459368 · Cited by 1
Glycemic and nonglycemic effects of pediatric diabetes in cardiovascular health
Flores, A., Ubico, E. M., Blacksher, K., Cleveland, E., Inman, L., Singer, I., Bond, C., Obiaka, U., & Perez-Garcia, E. M. (2024) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2024.101781 · Cited by 1
Chauhan, K., & Rani, S. (2024) · Journal of Applied and Natural Science · doi:10.31018/jans.v16i4.5994 · Cited by 1
“To lower the risk of complications and the condition's progression, tight control over blood pressure, glucose, and cholesterol levels is necessary (Ma et al ., 2022).”
Liu, K., Chen, H.-W., Wang, S.-A., Zhang, C., Cao, B., Zhang, X., Gu, S.-Y., Zhong, Q., Wei, Y., Liang, Y., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.03.039 · Cited by 1
Ko, H. Y., Jung, K., Cho, Y., Bea, S., Bae, J. H., Cho, Y. M., Rhee, S. Y., & Shin, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16416 · Cited by 1
Hoda, F., Arshad, M., Khan, M. A., Habib, M. A., & Najmi, A. K. (2025) · Nephrology · doi:10.1111/nep.70050 · Cited by 1
Elbanna, R. H. M., Elabd, S. O. A., Saleh, M. S. M., & Alghitany, S. I. A. (2025) · Disability and Rehabilitation · doi:10.1080/09638288.2025.2506824 · Cited by 1
“…been accompanied by an increase in obesity-related medical conditions, including cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2DM) [4], especially in male, and eventhough the health hazards linked to obesity in males, a limited number of men engage in weight control programs [5].”
Foddha, H., Jeddou, I. B., Saoud, H., Chouchène, S., Abdelhak, F., Jrad, B. B. H., Abdennabi, H. B., & Khelil, A. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-07785-x · Cited by 1
“In type 2 DM, CAD risk assessment and individualized glycemic management are essential, and recent guidelines emphasize precision medicine strategies to tailor treatment based on individual risk profiles 10 .”
Okorigba, E. M., Akinade, O. N., Emore, E., Adebayo, A. A., Aghale, O. S., Ekarika, E., Awuji, K., Olawale, O. O., Siaw, T. K., Azipu, R., et al. (2025) · Cureus · doi:10.7759/cureus.87886 · Cited by 1
Editorial: Non-coding RNA in diabetes and cardiovascular diseases
Mačvanin, M., Zafirovic, S. S., Obradovic, M. M., & Isenović, E. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149857 · Cited by 1
O’Sullivan, J. L., Alonso-Pérez, E., Färber, F., Fuellen, G., Rudolf, H., Heisig, J. P., Kreyenfeld, M. R., & Gellert, P. R. (2023) · Research Square · doi:10.21203/rs.3.rs-3210698/v1 · Cited by 1
Lee, D. Y. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0328 · Cited by 1
“It is also a major risk factor for cardiovascular disease (CVD), which remains a leading cause of death among patients with diabetes [1].”
BackgroundWang, J., su, T., Li, Y., Su, Y., & Li, Y. (2024) · medRxiv · doi:10.1101/2024.09.29.24314577 · Cited by 1
Self-citationKong, Y., Luo, Q., Zhang, Q., & Wei, Q. (2024) · Research Square · doi:10.21203/rs.3.rs-5305467/v1 · Cited by 1
Vastrad, B. M., Pattanashetti, S., Vastrad, C. M., & Bhandi, N. (2026) · Research Square · doi:10.21203/rs.3.rs-8562423/v1 · Cited by 1
Salman, M. N., Al-Kashwan, T. A. J., & Aljanabi, A. A. (2023) · Research Square · doi:10.21203/rs.3.rs-3279251/v1
Assaad-Khalil, S. H., Samna, S. G., Elebrashy, I., El-Nahas, M., El-Hefnawy, M. H., Eltoony, L. F., Elhadidy, K. E., El-Messallamy, F. A. F., Megallaa, M. H. Z., Khalifa, W. A. M., et al. (2023) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/10/1/001162
“Patients with type 2 diabetes mellitus are two to three times more likely to develop cardiovascular disease compared to those without diabetes [41].”
BackgroundCardiometabolic effect of sodium and glucosa cotransporter inhibitors type 2
Olmedo-Muñoz, M., & Recalde-Navarrete, R. J. (2023) · Salud Ciencia y Tecnología · doi:10.56294/saludcyt2023563
[Severe post-COVID-19 dialysis dependence and inpatient acute kidney injury]
Soto-Santillán, P., Pérez, F. P., Anda‐Garay, J. C., Silva-Rueda, R., Castillo-Cruz, J., Roy-García, I. A., Rivas-Ruíz, R., Palma-Díaz, E. J., Hernández-Rivera, J. C. H., & Paniagua, R. (2023) · PubMed Central · doi:10.5281/zenodo.8319781
Shereshneva, M. V., & Ilyin, M. V. (2023) · Медицинская этика · doi:10.24075/medet.2023.033
Assessment of Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus on Insulin Therapy
Shepelkevich, A. P., Баалбаки, Д. Д., Дыдышко, Ю. В., & Юреня, Е. В. (2023) · Рецепт · doi:10.34883/pi.2023.26.5.006
Correlation between cardiovascular risk and glycemic control among patients with diabetes
Dalimunthe, N. N., Ahmad, H., & Dalimunthe, D. A. (2024) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_167_23
Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysisPreprint
gong, X., cheng, P., han, Y., li, Q., Song, C., & Zhao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4159026/v1
Harms, P. P. (2024) · doi:10.5463/thesis.663
Upreti, B., Sherpa, M. L., & Bhutia, K. L. (2024) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v15i6.63068
Ken-Eze, U. C., Ozojide, K. O., Anamazobi, E. G., Okobi, O. E., Olawoye, A., & Efe, U. O. (2024) · Cardiology and Angiology An International Journal · doi:10.9734/ca/2024/v13i3422
Kemp, B. J., Thompson, D. R., COATES, V. E., Bond, S., Ski, C. F., Monaghan, M., & McGuigan, K. (2024) · Health Policy · doi:10.1016/j.healthpol.2024.105116
Bora, S., Adole, P. S., Vinod, K. V., Pillai, A. A., & Ahmed, S. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10881-8
“CVD affects 32.2% of diabetics and is the leading cause of mortality among them (Ma et al. 2022; Otto et al. 2023).”
InfluentialКовальчук, А., Zinych, О. В., Кушнарьова, Н. М., Ковальчук, В. М., Prybyla, О. В., & Shyshkan-Shyshova, К. О. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.4.2024.1407
Diabetes Mellitus tipo 2: fisiopatologia, diagnóstico, tratamento e complicações em clínica médica
Silveira, N. S., Rezende, C. D. O., Gonçalves, L. G., Moreira, L. S. R., & de Melo, T. N. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n4-357
Disease burden and symptom management in type 2 diabetic patients: A phenomenological study
Çam, S. D., & Uzun, S. (2024) · Public Health Nursing · doi:10.1111/phn.13404
Glycemic Control and Cardiometabolic Risk in Black Zimbabweans with Type 2 Diabetes Mellitus
Chiveto, D., Musarurwa, C., Mapira, H. T., Kaseke, F., Nyengerai, T., Kaseke, T., & Gori, E. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s473042
Mehra, A., Mittal, A., & Singh, S. (2024) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/0118715230325278240821053346
Song, M.-R., Jung, W.-N., Yoo, Y., Lee, M.-S., Ahn, Y., Ahn, S.-Y., & Lee, B.-C. (2024) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2024.45.4.602
Meng, Q., Ma, H., Tian, N., Wang, Z., Cai, L., Zhang, Y., Wang, Q., Zhen, R., Zhao, J., Wang, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40074
Prado, D. G., Justino, A. B., Silva, T. D. C., Morais, S. A. L., Martins, M. M., Santos, P. D. S., Cunha, L. C. S., Sousa, R., de Aquino, F. J. T., Espíndola, F. S., et al. (2024) · Journal of Mass Spectrometry · doi:10.1002/jms.5099
Muscle Glucose Metabolism in Metabolic Diseases
Eshima, H. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815313925124010003
Zeenny, R. M., Abdo, R., Haddad, C., Hajj, A., Zeidan, R. K., Salameh, P., & Ferrières, J. (2024) · Pharmacy · doi:10.3390/pharmacy12060171
Yin, B., Wang, T., Wu, Y., & Lv, J. (2024) · Research Square · doi:10.21203/rs.3.rs-5340040/v1
Giraldo, G. C., Fuentes, J. J., Arias, J. C., & Castaño-Molina, C. E. (2024) · medRxiv · doi:10.1101/2024.12.02.24318358
Zheng, S., Wu, Y., Li, A., Wu, Z., Liu, Z., Wang, H., Jia, X., Tsao, P. S., & Pan, C. (2024) · medRxiv · doi:10.1101/2024.12.24.24319595
Khan, Z., Khan, I., Haroon, M., Badshah, A., Wazir, M. Z., & Ullah, I. (2024) · Journal of Medical Sciences · doi:10.52764/jms.24.32.4.6
Keefe, M. S., Hernandez, M. I., Brojanac, A., Elliott, K. B., Moya, R. E., & Dunn, R. A. (2025) · The Journal of Physiology · doi:10.1113/jp287837
“If individuals with T2D were to integrate PHT into their treatment routines, we suspect we would find similar enhancements in metabolic and cardio-vascular health, potentially supporting the case for PHT as a standard component of care for patients with T2D.”
Boosting Blood Flow: How Warm Compress Helps Manage Blood Pressure in Type 2 Diabetes
Wardika, I. J., Widayati, N., Ridla, A. Z., & Setiawan, I. (2025) · Jurnal Kegawatdaruratan Medis Indonesia · doi:10.58545/jkmi.v4i1.419
Zheng, S., Zhou, D., Chen, F., & Zheng, J. (2025) · Journal of Medical Biochemistry · doi:10.5937/jomb0-55092
“Hydro - colloid dressings can also be applied to protect the area, and the healing process should be monitored (11–13).”
Andrade, F. A. L., Bello, N. F. S., Arias‐Botero, J. H., Bedoya, J. S., Buitrago, L. M. G., Chaves, A., & Barbosa, F. R. (2025) · Clinical and Public Health Guidelines · doi:10.1002/gin2.70019
Yu, Q., Ye, J., Wu, X., Xia, Y., Li, H.-X., Yang, L., Deng, X., & Yuan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01685-w
“Atherosclerotic cardiovascular disease (ASCVD) is a major macrovascular complication of T2DM that has become the leading cause of mortality and disability in patients with T2DM [2, 3], and its primary mechanism is atherosclerosis [4].”
Effect of semaglutide on c-peptide levels in patients with type 2 diabetes
Fan, P., & Ma, X. (2025) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2025.38.2.reg.13485.1
Self-citationFatima, H., Malik, A. P., Iqbal, J., & Suthian, B. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133313
Характеристика фенотипу пацієнтів із цукровим діабетом 2-го типу та ішемічною хворобою серця
Saienko, Y. A., & Mankovsky, B. (2025) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2025.2.2131
Kurt, O. (2025) · Black Sea Journal of Engineering and Science · doi:10.34248/bsengineering.1618267
“In contrast, T2DM, also known as insulin-independent diabetes, arises due to insulin resistance or insufficient insulin production and is predominantly diagnosed in middle-aged and older adults (Ma et al., 2022; Varma et al., 2014; Carrillo-Larco et al., 2024).”
Liu, M., Liu, F., Diljhumal, A., Yang, J., wang, Y., Ye, M., Jia, T., & Gao, Y. (2025) · medRxiv · doi:10.1101/2025.05.04.25326947
Gender Considerations and Omega-3 Fatty Acids in Cardiovascular Disease
Adekar, S. P., Zanwar, A. A., Hegde, M. V., & Salunkhe, K. (2025) · Springer eBooks · doi:10.1007/978-3-031-84200-9_3
Wang, Y., Liu, Y., Xu, M., Wang, M., Wang, X., Liu, W., Jiang, C., Tan, L., Liu, S., Sun, H., et al. (2025) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/5690902
“Studies have reported associations between T2DM and both microvascular and macrovascular dysfunction, including cardiovascular diseases (CVDs) [3], diabetic kidney disease (DKD) [4], retinopathy [5], peripheral neuropathy [6], and even neurodegenerative conditions such as Alzheimer’s [7] and…”
Mkhabela, S. M., Jaya, Z. N., & Thembane, N. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i6.1683
Peng, F., Long, Y., Zheng, T., Leng, M.-H., & Deng, H. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05332-w
Zhong, L., Lin, R., Cao, B., Zhong, W., Tu, M., & Wei, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1591108
“Previous studies have indicated that relatively high TSH levels was positively associated with unfavorable lipid concentration and cardiovascular risks in enthyroid people (2, 35).”
Zhou, B. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i6.499
Diastolic Dysfunction in Normotensive Adult with Type 2 Diabetes Mellitus in Bangladesh
Alam, M. S., Kalam, S. T., Hasan, M. M., Uddin, M. G., & Khan, F. N. (2025) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_9_25
IMPACT OF CELEBRITY STATEMENTS ON INTERNET SEARCHES ON THE USE OF SEMAGLUTIDE FOR WEIGHT LOSS
Local Health Unit of Trapani, A. T., Provenzano, S., Santangelo, O. E., & Regional Health Care and Social Agency of Lodi, A. L. (2025) · Avicenna Bulletin · doi:10.25005/2074-0581-2025-27-2-373-384
From the laboratory to the clinic: advancing helminthic therapy for type 2 diabetes
Zhu, Y., Fei, X., Wang, R., Wang, J., Liu, M., Zhang, Y., Li, X., Xu, J., Zhao, Q., Zhang, X., et al. (2025) · Journal of Helminthology · doi:10.1017/s0022149x25100576
Assinnari, A., & Althobaiti, S. (2025) · medRxiv · doi:10.1101/2025.08.07.25333260
Age-Related Characteristics of Diastolic Dysfunction in Type 2 Diabetes Patients
Grigorescu, E.-D., Mihai, B. M., Cazac, G.-D., Foșălău, A.-B., Onofriescu, A., Floria, M., Dascălu, C. G., Ceasovschih, A., Șorodoc, L., & Lăcătușu, C.-M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165772
“Early detection of subclinical cardiac dysfunction, allowing the initiation of therapies with proven cardiac benefits, can prevent the onset and progression of overt CVD, including heart failure with preserved ejection fraction (HFpEF), and therefore the risk of major cardiovascular events [1,2].”
Special Issue “Diabetes: Comorbidities, Therapeutics and Insights”
Bulum, T. (2025) · Biomedicines · doi:10.3390/biomedicines13092043
“The third review explores recent advancements in the management of patients with type 2 diabetes, their place in the new guidelines, and their role in the reduction of both microvascular and macrovascular complications [22].”
Research Progress on the Insulin Resistance-Modulating Effects of Gegen’s Chemical Components
贺, 岁. (2025) · Traditional Chinese Medicine · doi:10.12677/tcm.2025.148529
Xu, X., Shi, Y. P., Liu, H., Zhao, R., Cui, W., Shao, M., Yu, H., Yan, S., & Fu, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s541164
Yuan, X., Zhang, Z.-C., Li, J., Ye, S., & Zhou, W. P. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.104879
Ali, A., Sohail, U., Rao, T., Tariq, F., Baig, A., & Fatima, S. A. (2025) · Cureus · doi:10.7759/cureus.93303
CLINICAL AND PATHOPHYSIOLOGICAL SPECIFICITIES OF ATHEROSCLEROSIS IN PATIENTS WITH TYPE 2 DIABETES
Kosiński, M., Strzemkowska, M., Dotka, M., & Brzezińska, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3855
Serum Electrolytes and Their Combined Effect on Hyperuricemia among Type 2 Diabetic Patients
Begum, N., Rafi, U., Khalid, S., Hameed, S., Iqbal, N., Faridi, T. A., & Ullah, R. H. (2025) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v8i9.1298
Decoding the coronary paradox of obesity: not all fat is equal!
Santulli, G., Pande, S., Mone, P., & Varzideh, F. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101807
“…and technological innovations, the incidence of adverse cardiovascular events among individuals with type 2 diabetes remains high [1 – 3], underscoring the critical importance of ongoing research aimed at identifying modifiable risk factors, optimizing prevention strategies, and…”
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Huang, X., Yu, N., Yu, H., & Yang, S. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04624-z
“The possible explanation could be that: Higher GDF-15 is associated with an increased risk of cardiovascular diseases, and the latter is the major leading cause of death in diabetic patients [10, 40–42].”
Ubiquitination of glucose and lipid metabolic proteins is altered in diabetic rat livers
Abo‐Ali, E. M., Shetty, D. K., Khairnar, R., Kumar, S., & Dukhande, V. V. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124120 · Cited by 1
Pooja, Chaturvedi, S., Singh, S., Singh, S., & Modi, D. R. (2025) · International Journal of Biomolecules and Biomedicine | IJBB · doi:10.12692/ijbb/21.2.1-10
Shabil, M., Kasoj, M., Sulthana, H., Ullah, A., Verma, A., Sah, R., Mehta, R., & Babaresh, W. M. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s560762
New-Onset Type 2 Diabetes Mellitus in Critical Illness Survivors and after Hospitalization
Halpern, G. A., Nemet, M., Abramovich, S., Karakuş, İ. S., Garcia-Mendez, J. P., Tekin, A., Gowda, D. M., Kılıçkaya, O., Hassett, L. C., & Lal, A. (2025) · Southern Medical Journal · doi:10.14423/smj.0000000000001904
Liu, Y., Liu, J.-E., He, H., Qin, M., Lei, H., Meng, J., Liu, C., Chen, X., Luo, W., & Zhong, S. (2024) · Figshare · doi:10.6084/m9.figshare.26664169
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.25720305
Ayalew, T. L., Haile, K. E., Feleke, M. G., Zewudie, B. T., & Chichiabellu, T. Y. (2024) · Figshare · doi:10.6084/m9.figshare.26611901
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Abou-Samra, A. B., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.26714038
Ahmad, A., & Sabbour, H. M. (2024) · Figshare · doi:10.6084/m9.figshare.26695041
Paszek, E., Polak, M., Bryk, A. H., Konieczyńska, M., & Undas, A. (2024) · Figshare · doi:10.6084/m9.figshare.26604721
Szydełko, J., Czop, M., Petniak, A., Lenart-Lipińska, M., Kocki, J., Zapolski, T., & Matyjaszek‐Matuszek, B. (2024) · Figshare · doi:10.6084/m9.figshare.26755663
Moreno‐Vedia, J., Llop, D., Rodríguez‐Calvo, R., Plana, N., Amigó, N., Rosales, R., Esteban, Y., Girona, J., Masana, L., & Ibarretxe, D. (2023) · Figshare · doi:10.6084/m9.figshare.24144178
Liu, T., Fan, Z., Xiao, B., He, C., & Wang, S. (2024) · Figshare · doi:10.6084/m9.figshare.25478853
Liu, Y., Liu, J.-E., He, H., Qin, M., Lei, H., Meng, J., Liu, C., Chen, X., Luo, W., & Zhong, S. (2024) · Figshare · doi:10.6084/m9.figshare.26664160
Wang, H., Zu, Q., Tang, H., Lu, M., Chen, R., & Yang, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24054402
Ahmad, A., & Sabbour, H. M. (2024) · Figshare · doi:10.6084/m9.figshare.26695038
Liu, Y., Liu, J.-E., He, H., Qin, M., Lei, H., Meng, J., Liu, C., Chen, X., Luo, W., & Zhong, S. (2024) · Figshare · doi:10.6084/m9.figshare.26664166
Hu, J., Wang, X., Cheng, L., Dang, K., Ming, Z., Tao, X., Xu, X., Sarker, S., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26666467
Self-citationXia, Z., Song, L., Fang, D., You, W., Li, F., Zheng, D., Li, Y., Lin, L., Dou, J., Su, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22604788
Self-citationWang, Z., He, H., Xie, Y., Li, J., Luo, F., Sun, Z., Zheng, S., Yang, F., Li, X., Chen, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25310083
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.25720119
Hu, J., Wang, X., Cheng, L., Dang, K., Ming, Z., Tao, X., Xu, X., Sarker, S., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26666464
Self-citationElashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.26714032
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.26714044
Herashchenko, A. S., & Bielinskyi, M. V. (2025) · Терапевтика · doi:10.31793/2709-7404.2025.1-6.61
Tsay, E., Kurmaeva, D., Nuriddinov, S., Tsoy, V., Abduxalimova, S., Bozorov, S. S., Khalimova, Z., Engelsen, S. B., Magkos, F., Akbarovna, D. D., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03039-2
Golmohammadi, M., Attari, V. E., Salimi, Y., Saed, L., Nachvak, S. M., & Samadi, M. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01275-6
Metadata
- Authors
- Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B.
- Venue
- Cardiovascular Diabetology
- Published
- 2022-05-14
- Volume
- 21
- Issue
- 1
- Pages
- 74-74
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC9107726
- OpenAlex
- W4280586315
- Cited by
- 464
- References
- 137
- Citations by year
- 2026: 97 · 2025: 153 · 2024: 137 · 2023: 69 · 2022: 8
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- the Lanzhou Chengguan District Science and Technology Plan Project (2021-9-19)
- the hospital fund of the First Hospital of Lanzhou University (ldyyyn2020-93)
- the Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases (20JR10FA667)
- the Special Funds of Science and Technology Development of the Chinese Central Government to guide Local (1004TCYA032)
- the Gansu Provincial Natural Science Foundation (20JR10RA681)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, personalized medicine, cardiovascular risk management, glycemic control, blood pressure control, lipid-lowering therapy, glucose-lowering agents, antiplatelet therapy, cardiovascular disease prevention, low- and middle-income countries
- MeSH terms
- Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Lipids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
